Mallinckrodt and Terumo BCT Announce UVADEX(R) (Methoxsalen) A...
SYDNEY, Nov. 1, 2019 /PRNewswire-AsiaNet/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX(R) (methoxsalen) has received regulatory approval in...
Authors: LATEST ASIANET NEWS RELEASES